Indeed, the PI3K/Akt/mTOR pathway is over‐activated in various cancers; therefore, the pathway is an attractive therapeutic target because it functions as a convergence point for divergent growth stimuli and regulates cellular processes that are involved in the initiation and maintenance of cancer. This evidence concerns the gene AKT1 and cancer.